Real-world evidence on the use of daratumumab, bortezomib and dexamethasone (DVd) in lenalidomide-refractory myeloma patients: subgroup analysis of the multicenter retrospective experience by “rete ematologica pugliese”Giuseppe Mele, Domenico Pastore, Attilio Guarini et al.|Leukemia & lymphoma/Leukemia and lymphoma|2023Cited by 2
Single versus double autologous stem cell transplantation and lenalidomide maintenance versus no maintenance therapy in newly-diagnosed patients with multiple myeloma: a real-life, vintage snapshot after twenty-three years from the Rete Ematologica PuglieseNicola Di Renzo, Pellegrino Musto, Emanuela Resta et al.|Annals of Hematology|2025Cited by 0